Other relevant information

The communications of Other Relevant Information included in this section correspond exactly to those submitted to the Spanish securities market regulator (CNMV) and published on its website (www.cnmv.es ).

To consult all Oryzon Genomics, S.A. registered information, access the official registers of the CNMV .

 

11 May 2020
ORYZON submits a press release regarding the composition of its Board of Directors

11 May 2020
Publication of the Company‘s Results’ Information for the First Quarter 2020
Q1 2020 Financial Results CNMV format ( Spanish only)

24 April 2020
VAFIDEMSTAT from Oryzon Genomics S.A. receives approval to conduct a Phase II clinical trial in severely ill COVID-19 patients from the Spanish Drug Agency (AEMPS)

17 April 2020
ORYZON attaches a pressrelease relating to the contingency plans implemented by the Company with regard to the COVID-19 pandemic

17 April 2020
ORYZON announces the incorporation of a new Independent Director to its Board of Directors

3 April 2020
ORYZON presents preliminary efficacy data of vafidemstat from its two Phase IIa clinical trials in Alzheimer’s, REIMAGINE-AD and ETHERAL

25 February 2020
ORYZON sends press release regarding a change in its Board of Directors (Spanish)

24 February 2020
The company sends press release about 2019 Financial Results (Spanish)

24 February 2020
Publication of the Company’s Annual Director Remuneration Report for year 2019 (Spanish)

24 February 2020
Publication of the Company‘s Results’ Information for the second semester 2019 (Spanish)

24 February 2020
Corporate Governance Annual Report 2019 (Spanish)